StromaBio

Executive Summary

StromaBio AB is a clinical-stage biopharmaceutical company based in Stockholm, Sweden, founded in 2018. The company is developing allogeneic cell therapies based on mesenchymal stromal cells (MSCs) derived from bone marrow, targeting acute respiratory distress syndrome (ARDS) and Alzheimer's disease (AD). StromaBio's platform leverages the immunomodulatory and regenerative properties of MSCs, which have shown potential in reducing inflammation and promoting tissue repair. The company is currently in the preclinical stage, focusing on advancing its lead candidates toward clinical trials. With a strong scientific foundation and a clear focus on high-need indications, StromaBio represents a promising opportunity in the cell therapy space. However, as a preclinical company, it faces significant development risks and capital requirements. The estimated conviction score of 40 reflects these early-stage uncertainties balanced by the potential of its MSC platform for treating large-market diseases.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data for ARDS Program50% success
• Q1 2027IND/CTA Filing for First-in-Human Trial in ARDS30% success
• Q2 2027Partnership or Grant for Alzheimer's Program25% success